Chantibody Therapeutics

What Chantibody Therapeutics does

Chantibody Therapeutics is a privately-held biotechnology company, founded in 2021 and headquartered in Menlo Park, California, that discovers and develops therapeutics for life-threatening diseases with a primary focus on oncology. The company serves cancer patient populations with high unmet need — including colorectal cancer and other solid tumors — and, more recently, has signaled intent to address autoimmune diseases. Its core offering is an integrated in silico-empowered antibody discovery platform built around camelid-derived VHH (Variable Heavy chain of Heavy chain) antibodies, composed of three proprietary modules: VHHMAb® (high-throughput antigen-specific B-cell isolation combined with phage display and NGS repertoire analysis), MultiVHH™ (lineage-based multi-specific library construction guided by epitope geometry and thermodynamic linker design), and PathoVHH™ (disease-specific antibody discovery using native immunogen sources). These platforms feed a therapeutic pipeline that spans monoclonal antibodies, bispecifics, multi-specific antibodies (e.g., CT111, a PD-1 x CTLA-4 x VEGF trispecific), T cell engagers (CT224, a CDH17xCD3 biparatopic), and CAR-T programs including the CARP discovery engine, JL-Lightning (a non-viral, culture-free CAR-T manufacturing approach), and an MSLN + MUC1 dual-targeting CAR-T. Leadership comprises Qijun Qian (CEO), Wenfeng Xu (President and CSO), and Xinhao Wang (VP Bioinformatics and Ab Intelligence).

Chantibody is a pre-revenue, clinical/preclinical-stage company with no disclosed commercial product, partnership, or licensing revenue. Pricing is not publicly disclosed and would only be established post-regulatory approval. Go-to-market is conducted entirely through the scientific and investor community: the company disseminates data via conference posters at AACR and SITC, downloadable peer-style papers (e.g., on alpaca VHH diversity and Z15-0-2 antitumor activity), and a corporate website, with no traditional sales, marketing, or distribution apparatus. No funding rounds, M&A, pharma partnerships, or institutional investors are disclosed in the available record, though the leadership team's stated track record of advancing novel biologics to global clinical trials is positioned as a signal of forthcoming partnering or financing activity.

The business model is a hybrid platform-plus-asset biotech model: the VHH discovery stack generates internal therapeutic candidates (the "buy" path) while also creating an option to monetize the platform itself through future pharma collaborations or out-licensing of selected leads (the "partner" path). Customer segments are not end-patients but rather, prospectively, large-cap pharma partners and — if assets advance independently — hospital systems and specialty oncology centers conducting clinical trials. Headcount is in the 11–50 range, consistent with a lean discovery-stage organization that relies on outsourcing of clinical and manufacturing functions.

Name

Chantibody Therapeutics

Legal name

Chantibody Therapeutics Inc.

Website

https://chantibody.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Chantibody Therapeutics is a private, Menlo Park-based biotech that uses a proprietary VHH antibody discovery platform to develop cancer and autoimmune therapeutics, including multi-specific antibodies, T cell engagers, and CAR-T candidates.

Ownership category

akta.pro rank

Product category

Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), CAR-T & TCR-T Therapies (HLAAABAC), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Antibody therapeutics
• Cancer immunotherapy
• VHH antibody discovery
• CAR-T cell therapy
• Multi-specific antibodies

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Marketing channels3 records

Core offering

Chantibody Therapeutics develops antibody-based therapeutics for life-threatening diseases, especially cancer, using a proprietary VHH (Variable Heavy chain of Heavy chain) antibody discovery platform. The company combines machine learning, next-generation sequencing, and phage display to generate camelid-derived antibody drug leads across multiple modalities including monoclonal antibodies, multi-specific antibodies, fusion proteins, CAR-T cell therapies, and antibody conjugates. Lead therapeutic candidates include CT111, CT224, JL-Lightning CAR-T, and MSLN+MUC1 dual-targeting CAR-T programs.

Product overview

Chantibody Therapeutics is a biotech company offering an integrated ecosystem of antibody discovery platforms and therapeutic candidates. The core technology consists of three proprietary platforms: VHHMAb® (core VHH antibody discovery with NGS-based repertoire analysis), MultiVHH™ (multi-specific antibody library construction), and PathoVHH™ (disease-specific antibody discovery using native immunogen sources). These platforms support development of diverse therapeutic modalities including monoclonal antibodies, bispecific and multi-specific antibodies, fusion proteins, and CAR-T therapies. The company's lead programs include CT111 (PD-1/CTLA-4/VEGF trispecific antibody), CT224 (CDH17xCD3 T cell engager), JL-Lightning CAR-T (non-viral), and MSLN+MUC1 dual-targeting CAR-T, all in preclinical/clinical stages. The portfolio spans from discovery platforms enabling drug lead identification to differentiated therapeutic candidates targeting cancer.

Differentiator

Problem solved

Functional benefit

Brands

• VHHMAb®: VHH antibody discovery platform for multi-modality therapeutics development
• MultiVHH™
• PathoVHH™

Products and services

• VHHMAb Core VHH antibody discovery platform for biotech and pharmaceutical partners, enabling high-throughput antigen-specific B-cell isolation, phage display screening, and repertoire NGS analysis integrated with antibody intelligence to identify druggable sequences and best-in-class/first-in-class drug leads from camelid VHH and VH/NL repertoires.
• MultiVHH Multi-specific antibody library construction platform that selects lineage-based sequences from VHHMAb to design bispecific and multi-specific antibody candidates with optimal linkers based on epitope geometry and antibody intelligence, supporting therapeutic development partners.
• PathoVHH Disease-specific VHH discovery platform that uses native immunogen sources such as cells and tissues to generate VHH banks against proteins, non-proteins, and complexes, supporting target identification and antibody discovery for pathogen and oncology indications.
• CT111 PD-1 x CTLA-4 x VEGF trispecific antibody therapeutic candidate demonstrating potent anti-tumor efficacy through synergistic immune checkpoint blockade and VEGF inhibition with cooperative avidity, targeting oncology indications.
• CT224 Biparatopic VHH-based CDH17xCD3 T cell engager therapeutic candidate with optimized safety and efficacy for colorectal cancer; also described as a CD3 VHH-based multi-specific T cell engager platform with multiple leads for colorectal cancer and autoimmune diseases.
• JL-Lightning CAR-T Next-generation non-viral CAR-T cell therapy that does not require an in vitro culturing procedure, designed to deliver high clinical efficacy and good safety at low dosage for cancer indications.
• MSLN + MUC1 Dual-Targeting CAR-T CAR-T cell therapy candidate co-targeting MSLN (mesothelin) and MUC1 with conditional activation designed to improve tumor specificity and clinical safety for solid tumor indications.
• CARP High-throughput VHH discovery platform enabling rapid identification of potent antibody leads for CAR-T cell therapy development in oncology.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Poseida Therapeutics: Clinical-stage company developing non-viral CAR-T therapies using piggyBac and other transposon-based approaches. Closely comparable to Chantibody's JL-Lightning non-viral CAR-T concept with a similar manufacturing simplification thesis.
• Argenx: Commercial-stage leader in VHH/nanobody-based therapeutics (efgartigimod). Most directly comparable peer; both companies build on camelid VHH antibody discovery to develop multi-modality biologics, though Argenx is at vastly greater scale and clinical maturity.
• Harbour BioMed: Biotech developing fully human antibody platforms (H2L2 and HCAb/VHH) for immuno-oncology and immunology. Directly comparable as a VHH/nanobody platform company pursuing multi-specifics and ADCs, with similar platform-then-pipeline business model.
• Crescendo Biologics: Clinical-stage VHH/nanobody company developing T cell engagers and multi-specifics in oncology, including CDH17-targeted programs. Closely comparable therapeutic focus area (T cell engagers for solid tumors) using a similar VHH-based approach.

Broad incumbents

• Legend Biotech: Late-stage CAR-T company (with Janssen) commercializing ciltacabtagene autoleucel for multiple myeloma. A broadly comparable cell therapy peer at vastly greater scale, useful for understanding clinical and regulatory risk benchmarks.
• Allogene Therapeutics: Clinical-stage allogeneic CAR-T company with a broad pipeline of CAR-T therapies. Comparable on the CAR-T modality (including non-viral / scalable manufacturing ambitions) at significantly greater clinical and capital maturity.

Emerging players

• Elasmogen: Early-stage VHH/nanobody discovery company focused on developing soloMERs (humanized VHHs) for oncology and inflammation. Smaller-scope peer with similar VHH-based discovery and similar stage of development.
• Compass Therapeutics: Clinical-stage company developing multi-specific antibodies in oncology (e.g., CTX-009, CTX-1121). Closely comparable on the multi-specific antibody modality in oncology with a similar platform-then-pipeline structure.
• Atreca: Clinical-stage antibody discovery company using immune repertoire analysis (similar NGS-driven approach) to identify novel antibody therapeutics. Comparable on the wet-lab + NGS antibody discovery methodology.
• Caribou Biosciences: Clinical-stage cell therapy company with allogeneic CAR-T and iPSC-derived NK programs. Comparable as a smaller-stage cell therapy peer pursuing next-generation, scalable CAR-T manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chantibody-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chantibody Therapeutics